China (Mainland)
Premiumsupplier 
VGX-1027 CAS NO.6501-72-0
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- VGX-1027
- 4,5-Dihydro-3-phenyl-5-isoxazoleaceticacid;GIT 27;VGX-1027;3-Phenyl-2-isoxazoline-5-acetic acid;VGX 1027 3-Phenyl-2-isoxazoline-5-acetic acid;(S,R)-3-Phenyl-4,5-dihydro-5-isoxasole acetic acid;2-Isoxa
- 6501-72-0
Quick Details
- ProName: VGX-1027
- CasNo: 6501-72-0
- Molecular Formula: C11H11NO3
- Appearance: White crystal
- Application: CAS：6501-72-0； Small molecule inhibit...
- DeliveryTime: 3 months
- PackAge: 100g,500g,1kg,25kg/drum
- Port: shang hai
- ProductionCapacity: 1000 Gram/Month
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.
IC50 value:
Target: immunomodulator
Administration of VGX-1027 to NOD mice with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors markedly reduced the cumulative incidence of diabetes and insulitis. In addition, VGX-1027 given either i.p. or p.o. to CBA/H mice made diabetic with multiple low doses of streptozotocin successfully counteracted the development of destructive insulitis and hyperglycemia [1]. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA [2]. VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4+CD25- T cells in vitro and the development of clinical and histological signs of colitis in vivo [3].